US › Healthcare

Sera Prognostics Inc (SERA)

US · Healthcare · Medical Devices

$2.07+2.48%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

$30,000

Revenue YoY

+76.5%

Net profit

$-9.1M

EPS

$-0.18

EPS estimate

$-0.14

Net margin

-30,463.3%

EPS came in at -0.18 against a street estimate of -0.14 — a miss of 28.6%.

Key statistics

Market cap

$80.1M

Forward P/E

0.0

P/B

1.33

Book value

$1.51

EPS (TTM)

$-0.66

52-week high

$3.95

52-week low

$1.56

50-day MA

$2.05

200-day MA

$2.35

Beta

0.98

Analyst view

Analysts rate Sera Prognostics Inc a strong buy (2 buy, 0 hold, 0 sell out of 2) with an average price target of $5.50.

Shareholding

Insiders

12.17%

Institutions

50.21%

Largest institutional holders

Fund	Stake
Baker Bros Advisors LP	13.94%
Whetstone Capital Advisors, LLC	8.38%
Aberdeen Group PLC	6.98%
Vivo Capital, LLC	4.18%
Vanguard Capital Management, LLC	3.05%
CapTrust Financial Advisors	1.36%
Geode Capital Management, LLC	0.92%
Awm Investment Company Inc	0.53%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Sera Prognostics Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.